ALXO
Alx Oncology HoldingsNASDAQ
Healthcare • Biotechnology
Factor tilt: Micro-Cap Value
$1.16+0.43%
Close Nov 6, 2026
- Market cap
- $156.66M
- 1 month
- -2.1%
- 3 months
- -43.9%
- 1 year
- -8.3%
- 52-week range
- $0.89$2.60
- Dividend
- No dividends on record
- Next-quarter EPS estimate
- -$0.13Quarter to Sep 30, 2026 · 6 analysts · 0.0% in 30d
- Short interest
- 6.3% of float6M shares · settled Oct 15, 2026 · +5.3% since Sep 30, 2026 · FINRA
Fundamentals · trailing 12 months to Jun 30, 2026
- Revenue
- —
- Net income
- -$80.89M
- Free cash flow
- -$70.95M
- Book value
- $136.19M
- Total debt
- $9.71M
- P/E
- —
- Price / sales
- —
- Price / book
- 1.2×
- FCF yield
- -45.3%
- Net margin
- —
EODHD (TTM) · as of Nov 6, 2026
End-of-day close from stored market data, not a live quote.
About Alx Oncology Holdings
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer.
Read more
It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under phase 1b/2 trial for the treatment of breast cancer and other solid tumors; HER2 with an ADC, fam-trastuzumab deruxtecan-nxki, under phase 1 trial for the treatment of patients with breast cancer; ALX2004, under phase 1 clinical trial for treating solid tumors; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; and Sanofi with isatuximab and dexamethasone, under phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma. It has license agreements with Board of Trustees of Leland Stanford Junior University. The company was incorporated in 2015 and is headquartered in South San Francisco, California.
- Website
- alxoncology.com
- Headquarters
- South San Francisco, CA, United States
- Employees
- 48
- Listed
- Jul 17, 2020
- Fiscal year ends
- December
Company profile from EODHD, stored Oct 25, 2026.
Quarterly results
The last 8 fiscal quarters as reported (EODHD). Year over year compares the same quarter a year earlier.
| Quarter | Revenue | YoY | Gross margin | Op. income | Net income |
|---|---|---|---|---|---|
| Jun 2026filed Aug 6, 2026 | — | — | — | -$18.0M | -$18.0M |
| Mar 2026filed May 8, 2026 | — | — | — | -$19.0M | -$17.9M |
| Dec 2025filed Mar 9, 2026 | — | — | — | -$23.0M | -$22.8M |
| Sep 2025filed Nov 7, 2025 | — | — | — | -$22.5M | -$22.1M |
| Jun 2025filed Aug 12, 2025 | — | — | — | -$26.6M | -$25.9M |
| Mar 2025filed May 8, 2025 | — | — | — | -$31.8M | -$30.8M |
| Dec 2024filed Mar 6, 2025 | $868.0K | -65.0% | 50.0% | -$30.6M | -$29.2M |
| Sep 2024filed Nov 7, 2024 | — | — | — | -$32.6M | -$30.7M |
Fiscal years · last 6
| Fiscal year | Revenue | YoY | Gross margin | Op. income | Net income |
|---|---|---|---|---|---|
| Dec 2025filed Mar 9, 2026 | — | — | — | -$104.0M | -$101.7M |
| Dec 2024filed Mar 6, 2025 | — | — | — | -$142.5M | -$134.9M |
| Dec 2023filed Mar 7, 2024 | — | — | — | -$170.3M | -$160.8M |
| Dec 2022filed Mar 9, 2023 | — | — | — | -$127.4M | -$123.5M |
| Dec 2021filed Feb 28, 2022 | — | — | — | -$83.6M | -$83.5M |
| Dec 2020filed Mar 18, 2021 | $1.2M | -75.4% | 9.1% | -$43.7M | -$45.7M |
Short-interest history
FINRA reports open short positions for a settlement date. The publication date is later. These are reported positions, with a separate date for each observation.
Compare the reported short exposure around the dates you bought, sold or watched ALXO. A long position benefits from price rises; a short position benefits from falls. A change in these counts does not predict either move.
Settlement Oct 15, 2026
5,976,398 shares short
+303,261 shares (+5.3%) vs Sep 30, 2026
6.3% of the stored float. Published Oct 26, 2026.
Settlement Sep 30, 2026
5,673,137 shares short
-600,515 shares (-9.6%) vs Sep 15, 2026
6% of the stored float. Published Oct 9, 2026.
Settlement Sep 15, 2026
6,273,652 shares short
-791,150 shares (-11.2%) vs Aug 31, 2026
9.7% of the stored float. Published Sep 24, 2026.
Settlement Aug 31, 2026
7,064,802 shares short
-547,387 shares (-7.2%) vs Aug 14, 2026
11% of the stored float. Published Sep 10, 2026.
Settlement Aug 14, 2026
7,612,189 shares short
-106,069 shares (-1.4%) vs Jul 31, 2026
Share of float unavailable. Published Aug 25, 2026.
Settlement Jul 31, 2026
7,718,258 shares short
+258,047 shares (+3.5%) vs Jul 15, 2026
Share of float unavailable. Published Aug 11, 2026.
Change = this settlement’s shares short − the previous recorded settlement’s shares short; percentage change divides by that earlier count. A zero earlier count has no percentage change. Split-spanning counts are left uncompared. Float percentages use the stored settlement observation, not today’s float.
Source: stored FINRA equity short-interest records, up to six settlements from the last 240 days. FINRA data and reporting dates · How to read short interest
Dividends and stock splits
See the recorded cash amounts and dates behind ALXO’s income, and the splits that change its share count. Dates below are stored event records, not confirmation of a payment to your account.
Cash-dividend records
No qualified cash-dividend records are stored. This does not establish that the company pays no dividend.
Up to six Polygon cash-dividend events, including recorded ex-dates within the next 120 days. Amounts retain their recorded currency and decimal precision. Historical amounts are not restated to a common split basis, annualized, or converted to dollars.
For a long holding, compare the ex-date with when you held the shares and check the pay date against your broker’s cash history. Owning the stock today does not establish past entitlement. For a short holding, a dividend can create a payment obligation to the share lender.
Ex-dates and special dividend rules · Short-sale dividend obligations · Dividend data definitions
Split history
No qualified split events are stored. This does not establish that the stock has never split.
Up to six stored split dates through Nov 7, 2026. Equivalent vendor ratios are combined; conflicting ratios are left out. This history may be incomplete.
A split changes the share count and per-share price basis; it does not by itself add investment value. Put your holding’s earlier and later share counts on the same basis before comparing them. This applies to both long shares and shares owed on a short position.
How stock splits workPortfolio context
Sign in to see your position size
We’ll show you if ALXO is in your portfolio and how much it contributes.
Sign inMarket context
Loading market dates
Smart money context
Holder IQ: HIGH
24 smart-money holders: institutions with a high Holder IQ
Q2 2026, filed Sep 22, 2026
Smart-money 13F trend: unchanged (light)
Unlock crowding heatmapUnlock filer discoveryInsider context
Sentiment: neutral
Last trade: sell 81 days ago
Read the insider context evidence
What it means for you
Sign in to read your holdings or watchlist context. No personal position or direction is inferred.
What happened
Stored recent-activity label: neutral. This context label is separate from the scored insider signal read.
Why it can matter
A count of reported activity describes a sample, not purchase conviction, an insider’s intent or a future price move. Neutral is not an all-clear, and absent direction is not neutral evidence.
How we got this
The current context rule reads at most 50 nonduplicate issuer/share-class records filed in the last 90 days. It counts a bullish direction or purchase code P toward bullish, and a bearish direction or sale code S toward bearish. A side must exceed the opposite count by more than two to set its label; otherwise nonzero directional counts produce neutral. Calculation unavailable for this saved label: its counts, exact records, as-of time and rule version are not supplied here. Do not substitute the separate scored read’s different window or denominator.
Where the data comes from
Stored SEC Forms 3/4/5 insider-signal records, ordered by filing date with amendment duplicates excluded. Filing date is not transaction date. The last-trade line locates recent reported activity; it does not date or reconstruct the complete count.
Red flags: 0
Read the insider context evidence
What it means for you
Sign in to read your holdings or watchlist context. No personal position or direction is inferred.
What happened
Stored recent-activity label: neutral. This context label is separate from the scored insider signal read.
Why it can matter
A count of reported activity describes a sample, not purchase conviction, an insider’s intent or a future price move. Neutral is not an all-clear, and absent direction is not neutral evidence.
How we got this
The current context rule reads at most 50 nonduplicate issuer/share-class records filed in the last 90 days. It counts a bullish direction or purchase code P toward bullish, and a bearish direction or sale code S toward bearish. A side must exceed the opposite count by more than two to set its label; otherwise nonzero directional counts produce neutral. Calculation unavailable for this saved label: its counts, exact records, as-of time and rule version are not supplied here. Do not substitute the separate scored read’s different window or denominator.
Where the data comes from
Stored SEC Forms 3/4/5 insider-signal records, ordered by filing date with amendment duplicates excluded. Filing date is not transaction date. The last-trade line locates recent reported activity; it does not date or reconstruct the complete count.
Largest 13-F holders · Q2 2026
94 filers reported a long position in ALXO for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
The top 10 hold
69.3%
of the 105.2M shares 13-F filers reported
Moves vs Q1 2026
4 added2 trimmed
1 new · 3 unchanged
Net shares held
+1.3%
across the 9 holders with a comparable Q1 2026 book
| Rank | Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|---|
| 1 | RA CAPITAL MANAGEMENT, L.P. | $26.9M · 13M shares | 13M | Unchanged |
| 2 | venBio Partners LLC | $26.7M · 12.9M shares | 12.9M | Unchanged |
| 3 | BlackRock, Inc. | $15.3M · 7.4M shares | 7.4M | +1,552.4% |
| 4 | Redmile Group, LLC | $15.3M · 7.4M shares | 7.4M | -7.2% |
| 5 | Blackstone Inc. | $13.6M · 6.6M shares | 6.6M | +13.2% |
| 6 | DRIEHAUS CAPITAL MANAGEMENT LLC | $12.5M · 6M shares | 6M | +5.1% |
| 7 | SILVERARC CAPITAL MANAGEMENT, LLC | $11.9M · 5.7M shares | 5.7M | New |
| 8 | TCG Crossover Management, LLC | $11.7M · 5.7M shares | 5.7M | -56.5% |
| 9 | VANGUARD CAPITAL MANAGEMENT LLC | $10.3M · 5M shares | 5M | +19% |
| 10 | Vivo Capital, LLC | $6.6M · 3.2M shares | 3.2M | Unchanged |
Sign in to see each holder’s Holder IQ, factor-adjusted Holder IQ and rank, and compare these holders with all scored filers. Available on every plan.
Sign in5% holder filings (13D / 13G)
Holders of more than 5% of ALXO file with the SEC within days. A 13D holder may seek to influence the company; a 13G holder is passive. Each holder’s latest filing from the last three years.
| Filed | Holder | % of class |
|---|---|---|
| Oct 16, 2026 | CIK 150413013D · activist · amended | 9.99% |
| Aug 14, 2026 | TCG Crossover GP II LLC13G · passive · amended | 4.2%under 5% |
| Jul 27, 2026 | BlackRock, Inc.13G · passive | 5.4% |
| May 27, 2026 | LSV Associates LLC13D · activist · amended | 2.2%under 5% |
| May 15, 2026 | Redmile Group, LLC13G · passive · amended | 6.8% |
| May 15, 2026 | HBM Healthcare Investments Cayman Ltd13G · passive · amended | 6.5% |
| Apr 28, 2026 | MILLENNIUM MANAGEMENT LLC13G · passive · amended | 1.5%under 5% |
Get the Full Analysis for ALXO
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.